PIK3CA is implicated as an oncogene in ovarian cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1999-01

AUTHORS

Laleh Shayesteh, Yiling Lu, Wen-Lin Kuo, Russell Baldocchi, Tony Godfrey, Colin Collins, Daniel Pinkel, Bethan Powell, Gordon B. Mills, Joe W. Gray

ABSTRACT

Ovarian cancer is the leading cause of death from gynecological malignancy and the fourth leading cause of cancer death among American women1, yet little is known about its molecular aetiology. Studies using comparative genomic hybridization (CGH) have revealed several regions of recurrent, abnormal, DNA sequence copy number2, 3, 4 that may encode genes involved in the genesis or progression of the disease. One region at 3q26 found to be increased in copy number in approximately 40% of ovarian2 and other5 cancers contains PIK3CA, which encodes the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3-kinase). The association between PIK3CA copy number and PI3-kinase activity makes PIK3CA a candidate oncogene because a broad range of cancer-related functions have been associated with PI3-kinase mediated signalling6. These include proliferation7, glucose transport and catabolism8, cell adhesion9, apoptosis10, RAS signalling6 and oncogenic transformation11, 12, 13, 14. In addition, downstream effectors of PI3-kinase, AKT1 and AKT2, have been found to be amplified15, 16 or activated17 in human tumours, including ovarian cancer. We show here that PIK3CA is frequently increased in copy number in ovarian cancers, that the increased copy number is associated with increased PIK3CA transcription, p110α protein expression and PI3-kinase activity and that treatment with the PI3-kinase inhibitor LY294002 decreases proliferation and increases apoptosis. Our observations suggest PIK3CA is an oncogene that has an important role in ovarian cancer. More... »

PAGES

99-102

Journal

TITLE

Nature Genetics

ISSUE

1

VOLUME

21

Related Patents

  • Pharmaceutical Compounds
  • Thienopyrimidine Derivatives As P13k Inhibitors
  • Phosphoinositide 3-Kinase Inhibitor Compounds And Methods Of Use
  • Arylaminoalcohol-Substituted 2,3-Dihydroimidazo[1,2-C]Quinolines
  • Maleate Salts Of (E)-N-{4[3-Chloro-4-(2-Pyridinylmethoxy)Anilino]-3-Cyano-7-Ethoxy-6-Quinolinyl}-4-(Dimethylamino)-2-Butenamide And Crystalline Forms Thereof
  • Mutations Of The Pik3ca Gene In Human Cancers
  • Pharmaceutical Compounds
  • Antineoplastic Combinations With Mtor Inhibitor, Trastuzumab And/Or Hki-272
  • Phosphoinositide 3-Kinase Inhibitor Compounds And Methods Of Use
  • Polynucleotide Primers For Detecting Pik3ca Mutations
  • Rapamycin Coated Expandable Devices
  • Pyrazolopyrimidine Derivatives
  • Method For Treating Gefitinib Resistant Cancer
  • Phosphoinositide 3-Kinase Inhibitor Compounds And Methods Of Use
  • Phosphoinositide 3-Kinase Inhibitor Compounds And Methods Of Use
  • Receptor-Mediated Delivery: Compositions And Methods
  • Fused Pyrimidines Such As 2-(1h-Indol -4-Yl )-6-(4-Methyl-Piperazin-1-Ylmethyl)-4-Morpholin-4-Yl-Thieno[3,2-D]Pyrimidine, Uses As Phosphatidylinositol 3-Kinase Inhibitors, For The Treatment Of Cancer, Viral Infection, Inflammation, Metabolic, Endocrine, Immune And Cardiovascular Disorders
  • Pharmaceutical Compounds
  • Antineoplastic Combinations Containing Hki-272 And Vinorelbine
  • Chemical Compounds
  • Use Of Substituted 2,3-Dihydroimidazo[1,2-C]Quinazolines For Treating Lymphomas
  • 2—Amino—N— [7—Methoxy—2, 3-Dihydroimidazo-[1, 2-C] Quinazolin-5-Yl] Pyrimidine—5—Carboxamides
  • Method For Treating Gefitinib Resistant Cancer
  • Alkoxy-Substituted 2,3-Dihydroimidazo[1,2-C]Quinazolines
  • Phosphoinositide 3-Kinase Inhibitor Compounds And Methods Of Use
  • Use Of Substituted 2,3-Dihydroimidazo[1,2-C]Quinazolines For The Treatment Of Myeloma
  • Extraction Of Solvents From Drug Containing Polymer Reservoirs
  • Phosphatidylinositol-3-Kinase Pathway Biomarkers
  • Aminoalcohol Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Derivatives Useful For Treating Hyper-Proliferative Disorders And Diseases Associated With Angiogenesis
  • Therapeutic Agent Elution Control Process
  • Pharmaceutical Compounds
  • Treatment Regimen Utilizing Neratinib For Breast Cancer
  • Genetic Alterations Associated With Cancer
  • Fas Peptide Mimetics And Uses Thereof
  • Pharmaceutical Compounds
  • Erbb Interface Peptidomimetics And Methods Of Use Thereof
  • Device For Local And/Or Regional Delivery Employing Liquid Formulations Of Therapeutic Agents
  • Phosphoinositide 3-Kinase Inhibitor Compounds And Methods Of Use
  • Polynucleotide Primers For Detecting Pik3ca Mutations
  • Use Of Substituted 2,3-Dihydroimidazo[1,2-C]Quinazolines
  • Chromenone Derivatives
  • Pharmaceutical Compounds
  • Maleate Salts Of (E)-N-{4-[3-Chloro-4-(2-Pyridinylmethoxy)Anilino]-3-Cyano-7-Ethoxy-6-Quinolinyl}-4-(Dimethylamino)-2-Butenamide And Crystalline Forms Thereof
  • Antineoplastic Combinations Of 4-Anilino-3-Cyanoquinolines And Capecitabine
  • Solution Formulations Of Sirolimus And Its Analogs For Cad Treatment
  • Mutations Of The Pik3ca Gene In Human Cancers
  • Antineoplastic Combinations Containing Hki-272 And Vinorelbine
  • Methods Of Treating Ovarian Cancer By Modulating Snon
  • Alkoxy-Substituted 2,3-Dihydroimidazo[1,2-C]Quinazolines
  • Rapamycin Coated Expandable Devices
  • E.G., 5-(3-Pyridyl)-Cyclohexothieno(2',3'-5,6)Pyrimido-(3,4-A)-1,2,4- Triazole; Intracellular Signal Transduction; Treating Glioblastomas And Juvenile Myelomonocytic Leukemia.
  • Use Of Substituted 2,3-Dihydroimidazo[1,2-C]Quinazolines
  • Erbb Interface Peptidomimetics And Methods Of Use Thereof
  • Modulators Of Phosphoinositide 3-Kinase
  • Phosphatidylinositol-3-Kinase Pathway Biomarkers
  • Chemical Compounds
  • Pharmaceutical Compounds
  • Solution Formulations Of Sirolimus And Its Analogs For Cad Treatment
  • Device For Local And/Or Regional Delivery Employing Liquid Formulations Of Therapeutic Agents
  • Pharmaceutical Compounds
  • Maleate Salts Of (E)-N-{4-[3-Chloro-4-(2-Pyridinylmethoxy)Anilino]-3-Cyano-7-Ethoxy-6-Quinolinyl}-4-(Dimethylamino)-2-Butenamide And Crystalline Forms Thereof
  • Pharmaceutical Compounds
  • Combinations Of Substituted 2,3-Dihydroimidazo[1,2-C]Quinazolines
  • Drug Coated Expandable Devices
  • Pharmaceutical Compounds
  • Erbb Interface Peptidomimetics And Methods Of Use Thereof
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/5042

    DOI

    http://dx.doi.org/10.1038/5042

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1015487157

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/9916799


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Chromones", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Chromosomes, Human, Pair 3", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Enzyme Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "In Situ Hybridization, Fluorescence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Morpholines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Oncogenes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Ovarian Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Phosphatidylinositol 3-Kinases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Phosphoinositide-3 Kinase Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Cells, Cultured", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "UCSF Cancer Center, University of California, 941430-0808, San Francisco, California, USA", 
              "id": "http://www.grid.ac/institutes/grid.266102.1", 
              "name": [
                "UCSF Cancer Center, University of California, 941430-0808, San Francisco, California, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Shayesteh", 
            "givenName": "Laleh", 
            "id": "sg:person.0632011006.47", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632011006.47"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "MD Anderson Cancer Center, University of Texas, 77030, Houston, Texas, USA", 
              "id": "http://www.grid.ac/institutes/grid.240145.6", 
              "name": [
                "MD Anderson Cancer Center, University of Texas, 77030, Houston, Texas, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lu", 
            "givenName": "Yiling", 
            "id": "sg:person.015602724464.42", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015602724464.42"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "UCSF Cancer Center, University of California, 941430-0808, San Francisco, California, USA", 
              "id": "http://www.grid.ac/institutes/grid.266102.1", 
              "name": [
                "UCSF Cancer Center, University of California, 941430-0808, San Francisco, California, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kuo", 
            "givenName": "Wen-Lin", 
            "id": "sg:person.01331462570.14", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331462570.14"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "UCSF Cancer Center, University of California, 941430-0808, San Francisco, California, USA", 
              "id": "http://www.grid.ac/institutes/grid.266102.1", 
              "name": [
                "UCSF Cancer Center, University of California, 941430-0808, San Francisco, California, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Baldocchi", 
            "givenName": "Russell", 
            "id": "sg:person.01277711366.81", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277711366.81"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "UCSF Cancer Center, University of California, 941430-0808, San Francisco, California, USA", 
              "id": "http://www.grid.ac/institutes/grid.266102.1", 
              "name": [
                "UCSF Cancer Center, University of California, 941430-0808, San Francisco, California, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Godfrey", 
            "givenName": "Tony", 
            "id": "sg:person.01117017323.75", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117017323.75"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Life Sciences Division, Lawrence Berkeley National Laboratory, 94702, Berkeley, California, USA", 
              "id": "http://www.grid.ac/institutes/grid.184769.5", 
              "name": [
                "UCSF Cancer Center, University of California, 941430-0808, San Francisco, California, USA", 
                "Life Sciences Division, Lawrence Berkeley National Laboratory, 94702, Berkeley, California, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Collins", 
            "givenName": "Colin", 
            "id": "sg:person.013360254117.29", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013360254117.29"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Life Sciences Division, Lawrence Berkeley National Laboratory, 94702, Berkeley, California, USA", 
              "id": "http://www.grid.ac/institutes/grid.184769.5", 
              "name": [
                "UCSF Cancer Center, University of California, 941430-0808, San Francisco, California, USA", 
                "Life Sciences Division, Lawrence Berkeley National Laboratory, 94702, Berkeley, California, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Pinkel", 
            "givenName": "Daniel", 
            "id": "sg:person.014332747764.39", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014332747764.39"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "UCSF Cancer Center, University of California, 941430-0808, San Francisco, California, USA", 
              "id": "http://www.grid.ac/institutes/grid.266102.1", 
              "name": [
                "UCSF Cancer Center, University of California, 941430-0808, San Francisco, California, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Powell", 
            "givenName": "Bethan", 
            "id": "sg:person.01235741056.68", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235741056.68"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "MD Anderson Cancer Center, University of Texas, 77030, Houston, Texas, USA", 
              "id": "http://www.grid.ac/institutes/grid.240145.6", 
              "name": [
                "MD Anderson Cancer Center, University of Texas, 77030, Houston, Texas, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Mills", 
            "givenName": "Gordon B.", 
            "id": "sg:person.012742742357.13", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012742742357.13"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Life Sciences Division, Lawrence Berkeley National Laboratory, 94702, Berkeley, California, USA", 
              "id": "http://www.grid.ac/institutes/grid.184769.5", 
              "name": [
                "UCSF Cancer Center, University of California, 941430-0808, San Francisco, California, USA", 
                "Life Sciences Division, Lawrence Berkeley National Laboratory, 94702, Berkeley, California, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gray", 
            "givenName": "Joe W.", 
            "id": "sg:person.014525340267.00", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014525340267.00"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/bf02618290", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049897858", 
              "https://doi.org/10.1007/bf02618290"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1201605", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044882986", 
              "https://doi.org/10.1038/sj.onc.1201605"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/385544a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031372205", 
              "https://doi.org/10.1038/385544a0"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1999-01", 
        "datePublishedReg": "1999-01-01", 
        "description": "Ovarian cancer is the leading cause of death from gynecological malignancy and the fourth leading cause of cancer death among American women1, yet little is known about its molecular aetiology. Studies using comparative genomic hybridization (CGH) have revealed several regions of recurrent, abnormal, DNA sequence copy number2,\n                3,\n                4 that may encode genes involved in the genesis or progression of the disease. One region at 3q26 found to be increased in copy number in approximately 40% of ovarian2 and other5 cancers contains PIK3CA, which encodes the p110\u03b1 catalytic subunit of phosphatidylinositol 3-kinase (PI3-kinase). The association between PIK3CA copy number and PI3-kinase activity makes PIK3CA a candidate oncogene because a broad range of cancer-related functions have been associated with PI3-kinase mediated signalling6. These include proliferation7, glucose transport and catabolism8, cell adhesion9, apoptosis10, RAS signalling6 and oncogenic transformation11,\n                12,\n                13,\n                14. In addition, downstream effectors of PI3-kinase, AKT1 and AKT2, have been found to be amplified15,\n                16 or activated17 in human tumours, including ovarian cancer. We show here that PIK3CA is frequently increased in copy number in ovarian cancers, that the increased copy number is associated with increased PIK3CA transcription, p110\u03b1 protein expression and PI3-kinase activity and that treatment with the PI3-kinase inhibitor LY294002 decreases proliferation and increases apoptosis. Our observations suggest PIK3CA is an oncogene that has an important role in ovarian cancer.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/5042", 
        "isAccessibleForFree": false, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2435643", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.2682505", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1103138", 
            "issn": [
              "1061-4036", 
              "1546-1718"
            ], 
            "name": "Nature Genetics", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "21"
          }
        ], 
        "keywords": [
          "PI3-kinase activity", 
          "comparative genomic hybridization", 
          "PI3-kinase", 
          "copy number", 
          "PI3-kinase inhibitor LY294002", 
          "cancer-related functions", 
          "p110\u03b1 catalytic subunit", 
          "catalytic subunit", 
          "DNA sequences", 
          "downstream effectors", 
          "inhibitor LY294002", 
          "molecular etiology", 
          "candidate oncogene", 
          "glucose transport", 
          "genomic hybridization", 
          "oncogene", 
          "protein expression", 
          "PIK3CA transcription", 
          "human tumors", 
          "ovarian cancer", 
          "important role", 
          "transcription", 
          "PIK3CA", 
          "phosphatidylinositol", 
          "genes", 
          "subunits", 
          "Akt2", 
          "LY294002", 
          "AKT1", 
          "effectors", 
          "number2", 
          "apoptosis", 
          "hybridization", 
          "sequence", 
          "expression", 
          "broad range", 
          "proliferation", 
          "activity", 
          "cancer", 
          "region", 
          "death", 
          "role", 
          "number", 
          "gynecological malignancies", 
          "fourth leading cause", 
          "progression", 
          "cause of death", 
          "transport", 
          "function", 
          "cancer death", 
          "leading cause", 
          "addition", 
          "disease", 
          "association", 
          "cause", 
          "tumors", 
          "study", 
          "observations", 
          "malignancy", 
          "genesis", 
          "etiology", 
          "range", 
          "recurrent", 
          "treatment", 
          "Women1"
        ], 
        "name": "PIK3CA is implicated as an oncogene in ovarian cancer", 
        "pagination": "99-102", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1015487157"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/5042"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "9916799"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/5042", 
          "https://app.dimensions.ai/details/publication/pub.1015487157"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-11-24T20:49", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_307.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/5042"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/5042'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/5042'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/5042'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/5042'


     

    This table displays all metadata directly associated to this object as RDF triples.

    260 TRIPLES      21 PREDICATES      106 URIs      95 LITERALS      19 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/5042 schema:about N06c7a22a1dd541d0bacc3aacc6462880
    2 N0ded3f3952c4455b833f84164f0ccb6d
    3 N20231f51666341a2ad2153ee34fbe085
    4 N21924e5f659347fabff02bb560cf89fa
    5 N3e603bd927a34f009afe24bc92da53ce
    6 N66214946bde6491d83a0ceec45589e6f
    7 N8c7e78c2b33646979563031ab7e9e25c
    8 Nbdf4a652de04427a983966e7ec498b91
    9 Nc4fff35602d14ba29c3c73b89890b48b
    10 Nd49fd44900934470aa3019fc9a00a2e1
    11 Nf2cae6a5463445ab84488b4552d42d4a
    12 Nf33bd81265564aac80971c3f1312db69
    13 anzsrc-for:11
    14 anzsrc-for:1112
    15 schema:author N6c86ef1d60cd4b81b4929d769bdb9e21
    16 schema:citation sg:pub.10.1007/bf02618290
    17 sg:pub.10.1038/385544a0
    18 sg:pub.10.1038/sj.onc.1201605
    19 schema:datePublished 1999-01
    20 schema:datePublishedReg 1999-01-01
    21 schema:description Ovarian cancer is the leading cause of death from gynecological malignancy and the fourth leading cause of cancer death among American women1, yet little is known about its molecular aetiology. Studies using comparative genomic hybridization (CGH) have revealed several regions of recurrent, abnormal, DNA sequence copy number2, 3, 4 that may encode genes involved in the genesis or progression of the disease. One region at 3q26 found to be increased in copy number in approximately 40% of ovarian2 and other5 cancers contains PIK3CA, which encodes the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3-kinase). The association between PIK3CA copy number and PI3-kinase activity makes PIK3CA a candidate oncogene because a broad range of cancer-related functions have been associated with PI3-kinase mediated signalling6. These include proliferation7, glucose transport and catabolism8, cell adhesion9, apoptosis10, RAS signalling6 and oncogenic transformation11, 12, 13, 14. In addition, downstream effectors of PI3-kinase, AKT1 and AKT2, have been found to be amplified15, 16 or activated17 in human tumours, including ovarian cancer. We show here that PIK3CA is frequently increased in copy number in ovarian cancers, that the increased copy number is associated with increased PIK3CA transcription, p110α protein expression and PI3-kinase activity and that treatment with the PI3-kinase inhibitor LY294002 decreases proliferation and increases apoptosis. Our observations suggest PIK3CA is an oncogene that has an important role in ovarian cancer.
    22 schema:genre article
    23 schema:isAccessibleForFree false
    24 schema:isPartOf N94c4ca88d60e4f9ba706123d939e4e4a
    25 Nd9c88343e3114ee09dbc1879659e52b1
    26 sg:journal.1103138
    27 schema:keywords AKT1
    28 Akt2
    29 DNA sequences
    30 LY294002
    31 PI3-kinase
    32 PI3-kinase activity
    33 PI3-kinase inhibitor LY294002
    34 PIK3CA
    35 PIK3CA transcription
    36 Women1
    37 activity
    38 addition
    39 apoptosis
    40 association
    41 broad range
    42 cancer
    43 cancer death
    44 cancer-related functions
    45 candidate oncogene
    46 catalytic subunit
    47 cause
    48 cause of death
    49 comparative genomic hybridization
    50 copy number
    51 death
    52 disease
    53 downstream effectors
    54 effectors
    55 etiology
    56 expression
    57 fourth leading cause
    58 function
    59 genes
    60 genesis
    61 genomic hybridization
    62 glucose transport
    63 gynecological malignancies
    64 human tumors
    65 hybridization
    66 important role
    67 inhibitor LY294002
    68 leading cause
    69 malignancy
    70 molecular etiology
    71 number
    72 number2
    73 observations
    74 oncogene
    75 ovarian cancer
    76 p110α catalytic subunit
    77 phosphatidylinositol
    78 progression
    79 proliferation
    80 protein expression
    81 range
    82 recurrent
    83 region
    84 role
    85 sequence
    86 study
    87 subunits
    88 transcription
    89 transport
    90 treatment
    91 tumors
    92 schema:name PIK3CA is implicated as an oncogene in ovarian cancer
    93 schema:pagination 99-102
    94 schema:productId N464f36b7399b4becacf4a2fdfaec4f95
    95 N50f00871f19c400f97fcdfda921605e7
    96 N59a19c00bda0411fadb5afe4f8e3e691
    97 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015487157
    98 https://doi.org/10.1038/5042
    99 schema:sdDatePublished 2022-11-24T20:49
    100 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    101 schema:sdPublisher N8c6b5e1192a1498fac30ef2fd75eb9e1
    102 schema:url https://doi.org/10.1038/5042
    103 sgo:license sg:explorer/license/
    104 sgo:sdDataset articles
    105 rdf:type schema:ScholarlyArticle
    106 N06c7a22a1dd541d0bacc3aacc6462880 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    107 schema:name Humans
    108 rdf:type schema:DefinedTerm
    109 N07e1dff804594695b03d174935934f43 rdf:first sg:person.01277711366.81
    110 rdf:rest Nf30c1cb8cba34ba8b21855b6ba8c4fe6
    111 N0cf53b6cc8b74b94ac718ca5895b514d rdf:first sg:person.013360254117.29
    112 rdf:rest N9b8da69f2c694c3b808826f4d9659a24
    113 N0ded3f3952c4455b833f84164f0ccb6d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    114 schema:name In Situ Hybridization, Fluorescence
    115 rdf:type schema:DefinedTerm
    116 N20231f51666341a2ad2153ee34fbe085 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    117 schema:name Tumor Cells, Cultured
    118 rdf:type schema:DefinedTerm
    119 N21924e5f659347fabff02bb560cf89fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    120 schema:name Chromosomes, Human, Pair 3
    121 rdf:type schema:DefinedTerm
    122 N3e603bd927a34f009afe24bc92da53ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    123 schema:name Phosphatidylinositol 3-Kinases
    124 rdf:type schema:DefinedTerm
    125 N464f36b7399b4becacf4a2fdfaec4f95 schema:name pubmed_id
    126 schema:value 9916799
    127 rdf:type schema:PropertyValue
    128 N4cbf9059da3f4c70927b4b89a7225d50 rdf:first sg:person.012742742357.13
    129 rdf:rest Nd7408356a6644bddad8cb922c820fec7
    130 N50f00871f19c400f97fcdfda921605e7 schema:name dimensions_id
    131 schema:value pub.1015487157
    132 rdf:type schema:PropertyValue
    133 N59a19c00bda0411fadb5afe4f8e3e691 schema:name doi
    134 schema:value 10.1038/5042
    135 rdf:type schema:PropertyValue
    136 N66214946bde6491d83a0ceec45589e6f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    137 schema:name Phosphoinositide-3 Kinase Inhibitors
    138 rdf:type schema:DefinedTerm
    139 N6c86ef1d60cd4b81b4929d769bdb9e21 rdf:first sg:person.0632011006.47
    140 rdf:rest Naa6f5320450349fb834604db38ef5e10
    141 N8c6b5e1192a1498fac30ef2fd75eb9e1 schema:name Springer Nature - SN SciGraph project
    142 rdf:type schema:Organization
    143 N8c7e78c2b33646979563031ab7e9e25c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    144 schema:name Chromones
    145 rdf:type schema:DefinedTerm
    146 N8f97b2cdbce74f82850ee5751109dcdf rdf:first sg:person.01331462570.14
    147 rdf:rest N07e1dff804594695b03d174935934f43
    148 N94c4ca88d60e4f9ba706123d939e4e4a schema:issueNumber 1
    149 rdf:type schema:PublicationIssue
    150 N9b8da69f2c694c3b808826f4d9659a24 rdf:first sg:person.014332747764.39
    151 rdf:rest Nd5245eafe9d1494bb1e522b34d0a0565
    152 Naa6f5320450349fb834604db38ef5e10 rdf:first sg:person.015602724464.42
    153 rdf:rest N8f97b2cdbce74f82850ee5751109dcdf
    154 Nbdf4a652de04427a983966e7ec498b91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    155 schema:name Ovarian Neoplasms
    156 rdf:type schema:DefinedTerm
    157 Nc4fff35602d14ba29c3c73b89890b48b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    158 schema:name Enzyme Inhibitors
    159 rdf:type schema:DefinedTerm
    160 Nd49fd44900934470aa3019fc9a00a2e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    161 schema:name Oncogenes
    162 rdf:type schema:DefinedTerm
    163 Nd5245eafe9d1494bb1e522b34d0a0565 rdf:first sg:person.01235741056.68
    164 rdf:rest N4cbf9059da3f4c70927b4b89a7225d50
    165 Nd7408356a6644bddad8cb922c820fec7 rdf:first sg:person.014525340267.00
    166 rdf:rest rdf:nil
    167 Nd9c88343e3114ee09dbc1879659e52b1 schema:volumeNumber 21
    168 rdf:type schema:PublicationVolume
    169 Nf2cae6a5463445ab84488b4552d42d4a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    170 schema:name Morpholines
    171 rdf:type schema:DefinedTerm
    172 Nf30c1cb8cba34ba8b21855b6ba8c4fe6 rdf:first sg:person.01117017323.75
    173 rdf:rest N0cf53b6cc8b74b94ac718ca5895b514d
    174 Nf33bd81265564aac80971c3f1312db69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    175 schema:name Female
    176 rdf:type schema:DefinedTerm
    177 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    178 schema:name Medical and Health Sciences
    179 rdf:type schema:DefinedTerm
    180 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    181 schema:name Oncology and Carcinogenesis
    182 rdf:type schema:DefinedTerm
    183 sg:grant.2435643 http://pending.schema.org/fundedItem sg:pub.10.1038/5042
    184 rdf:type schema:MonetaryGrant
    185 sg:grant.2682505 http://pending.schema.org/fundedItem sg:pub.10.1038/5042
    186 rdf:type schema:MonetaryGrant
    187 sg:journal.1103138 schema:issn 1061-4036
    188 1546-1718
    189 schema:name Nature Genetics
    190 schema:publisher Springer Nature
    191 rdf:type schema:Periodical
    192 sg:person.01117017323.75 schema:affiliation grid-institutes:grid.266102.1
    193 schema:familyName Godfrey
    194 schema:givenName Tony
    195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117017323.75
    196 rdf:type schema:Person
    197 sg:person.01235741056.68 schema:affiliation grid-institutes:grid.266102.1
    198 schema:familyName Powell
    199 schema:givenName Bethan
    200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235741056.68
    201 rdf:type schema:Person
    202 sg:person.012742742357.13 schema:affiliation grid-institutes:grid.240145.6
    203 schema:familyName Mills
    204 schema:givenName Gordon B.
    205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012742742357.13
    206 rdf:type schema:Person
    207 sg:person.01277711366.81 schema:affiliation grid-institutes:grid.266102.1
    208 schema:familyName Baldocchi
    209 schema:givenName Russell
    210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277711366.81
    211 rdf:type schema:Person
    212 sg:person.01331462570.14 schema:affiliation grid-institutes:grid.266102.1
    213 schema:familyName Kuo
    214 schema:givenName Wen-Lin
    215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331462570.14
    216 rdf:type schema:Person
    217 sg:person.013360254117.29 schema:affiliation grid-institutes:grid.184769.5
    218 schema:familyName Collins
    219 schema:givenName Colin
    220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013360254117.29
    221 rdf:type schema:Person
    222 sg:person.014332747764.39 schema:affiliation grid-institutes:grid.184769.5
    223 schema:familyName Pinkel
    224 schema:givenName Daniel
    225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014332747764.39
    226 rdf:type schema:Person
    227 sg:person.014525340267.00 schema:affiliation grid-institutes:grid.184769.5
    228 schema:familyName Gray
    229 schema:givenName Joe W.
    230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014525340267.00
    231 rdf:type schema:Person
    232 sg:person.015602724464.42 schema:affiliation grid-institutes:grid.240145.6
    233 schema:familyName Lu
    234 schema:givenName Yiling
    235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015602724464.42
    236 rdf:type schema:Person
    237 sg:person.0632011006.47 schema:affiliation grid-institutes:grid.266102.1
    238 schema:familyName Shayesteh
    239 schema:givenName Laleh
    240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632011006.47
    241 rdf:type schema:Person
    242 sg:pub.10.1007/bf02618290 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049897858
    243 https://doi.org/10.1007/bf02618290
    244 rdf:type schema:CreativeWork
    245 sg:pub.10.1038/385544a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031372205
    246 https://doi.org/10.1038/385544a0
    247 rdf:type schema:CreativeWork
    248 sg:pub.10.1038/sj.onc.1201605 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044882986
    249 https://doi.org/10.1038/sj.onc.1201605
    250 rdf:type schema:CreativeWork
    251 grid-institutes:grid.184769.5 schema:alternateName Life Sciences Division, Lawrence Berkeley National Laboratory, 94702, Berkeley, California, USA
    252 schema:name Life Sciences Division, Lawrence Berkeley National Laboratory, 94702, Berkeley, California, USA
    253 UCSF Cancer Center, University of California, 941430-0808, San Francisco, California, USA
    254 rdf:type schema:Organization
    255 grid-institutes:grid.240145.6 schema:alternateName MD Anderson Cancer Center, University of Texas, 77030, Houston, Texas, USA
    256 schema:name MD Anderson Cancer Center, University of Texas, 77030, Houston, Texas, USA
    257 rdf:type schema:Organization
    258 grid-institutes:grid.266102.1 schema:alternateName UCSF Cancer Center, University of California, 941430-0808, San Francisco, California, USA
    259 schema:name UCSF Cancer Center, University of California, 941430-0808, San Francisco, California, USA
    260 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...